Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Molecular Hydrogen Supplement in Rheumatologic and Metabolic Patients
NCT05196295Phase 1Unknown
- Sponsor
- HoHo Biotech
- Start
- Jan 2022
- Primary completion
- Jul 2022
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Molecular hydrogen in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), metabolic syndrome and 1 more (3 arms), sponsored by HoHo Biotech. Primary endpoint: Adverse effects/symptoms at 28 days. Status: unknown.
02
Drugs
Molecular hydrogen
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)metabolic syndrometype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05196295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05196295.